-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Lj2GmktFj/kt110rUbpeTB7hsmuy7jsqW3nwtq6Q+SsbqPNTKopcOSkBLLpGL5c8 qdsFEoNc+p06Be/x1wk+7Q== 0000875320-09-000021.txt : 20090422 0000875320-09-000021.hdr.sgml : 20090422 20090422150127 ACCESSION NUMBER: 0000875320-09-000021 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20090421 FILED AS OF DATE: 20090422 DATE AS OF CHANGE: 20090422 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 130 WAVERLY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139-4242 BUSINESS PHONE: 6165776000 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Graves Kurt CENTRAL INDEX KEY: 0001406337 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 09763712 MAIL ADDRESS: STREET 1: C/O VERTEX PHARMACEUTICALS INCORPORATED STREET 2: 130 WAVERLY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 edgar.xml PRIMARY DOCUMENT X0303 4 2009-04-21 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001406337 Graves Kurt C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY STREET CAMBRIDGE MA 02139 0 1 0 0 EVP, Chief Commercial Officer Common Stock 2009-04-21 4 S 0 283 26.72 D 67965 D Common Stock 2009-04-21 4 S 0 210 27.34 D 67755 D Common Stock 250 I 401(k) Transaction made pursuant to Mr. Graves' company approved trading plan established under Rule 10b5-1. Open market sales reported on this line occurred at a wieghted average price of $26.72 (range $26.51 to ($26.97). Open market sales reported on this line occurred at a weighted average price of $27.34 (range $27.19 to $27.65). Mr. Graves undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Kenneth S. Boger, Attorney-In-Fact 2009-04-22 -----END PRIVACY-ENHANCED MESSAGE-----